Broadwood opposes revised STAAR Surgical-Alcon deal, cites board dissent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
December 11, 2025 7:00 AM ESTEncouraged that at Least One Member of STAARs Board Recognizes the Flaws of the Sale Process and that the Go-Shop Process was Performative
Questions Completeness of Disclosures Given Critical Omission of Inbound Interest from Respected Private Equity Firm that Indicated It Would Pay More than Alcon
Notes That STAARs Board Did Not Obtain an Updated Fairness Opinion on the Revised Terms, Despite Meaningful Improvement in Peer Valuations
Releases Investor Presentation with Updated Analysis Demonstrating Why STAAR Shareholders Should Vote AGAINST the Proposed... More
